Actinium Pharmaceuticals obtains FDA clearance for trial of Iomab-ACT in sickle cell disease
July 26, 2024
Actinium Pharmaceuticals Inc. has received FDA clearance of an IND application to study Iomab-ACT for targeted conditioning prior to a bone marrow transplant (BMT) in patients with sickle cell disease.